Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1978 1
1980 3
1984 3
1986 2
1987 1
1988 2
1989 1
1990 4
1991 7
1992 7
1993 7
1994 16
1995 14
1996 13
1997 11
1998 13
1999 14
2000 12
2001 8
2002 14
2003 15
2004 12
2005 16
2006 25
2007 15
2008 16
2009 17
2010 20
2011 23
2012 19
2013 18
2014 13
2015 19
2016 23
2017 15
2018 15
2019 17
2020 15
2021 13
2022 11
2023 3
2024 5
2025 5
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

452 results

Results by year

Filters applied: . Clear all
Page 1
Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis.
Zhang L, Wang C, Han D, Wang X, Zhao Y, Liu J. Zhang L, et al. Int Arch Allergy Immunol. 2009;148(2):161-9. doi: 10.1159/000155747. Epub 2008 Sep 19. Int Arch Allergy Immunol. 2009. PMID: 18802361 Clinical Trial.
METHODS: The trial was a prospective and randomized study involving 96 patients with persistent AR, aged 14-60 years, who were allergic to Dermatophagoides pteronyssinus. While 48 patients were randomly assigned to the cluster schedule reaching the maintenance dose …
METHODS: The trial was a prospective and randomized study involving 96 patients with persistent AR, aged 14-60 years, who were allergic to …
Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy.
Tabar AI, Muro MD, García BE, Alvarez MJ, Acero S, Rico P, Olaguíbel JM. Tabar AI, et al. J Investig Allergol Clin Immunol. 1999 May-Jun;9(3):155-64. J Investig Allergol Clin Immunol. 1999. PMID: 10412677 Clinical Trial.
We designed a cluster schedule of immunotherapy for patients allergic to Dermatophagoides pteronyssinus to reach the maximal recommended dose in 7 weeks. We compared its safety and clinical efficacy with those of a conventional schedule in a controlled trial. ...In …
We designed a cluster schedule of immunotherapy for patients allergic to Dermatophagoides pteronyssinus to reach the maximal r …
A large scale multicentre randomized, placebo-controlled subcutaneous house dust mite allergen immunotherapy (HDM SCIT) in allergic rhinitis: MITAR Study.
Suratannon N, Limsuwan T, Tantilipikorn P, Chatchatee P, Saengapaswiriya A, Boonpiyathad T, Thongngarm T, Roongpuvapaht B, Chantaphakul H, Kulalert P, Thanaviratananich S, Sangsupawanich P, Fooanant S, Manuyakorn W, Chusakul S, Piboonpochanun O, Apornpong T, Wongpiyabovorn J, Ruxrungtham K; MITAR Study Group. Suratannon N, et al. Asian Pac J Allergy Immunol. 2024 Sep;42(3):233-245. doi: 10.12932/AP-221123-1735. Asian Pac J Allergy Immunol. 2024. PMID: 39417769 Free article. Clinical Trial.
METHODS: We conducted a randomized, placebo-controlled trial comparing HDM SCIT against placebo in Dermatophagoides pteronyssinus (Der p) sensitized. All patients received standard of care according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline, inc …
METHODS: We conducted a randomized, placebo-controlled trial comparing HDM SCIT against placebo in Dermatophagoides pteronyssinus …
Clinical Trial With a Depigmented, Polymerized Mite Mixture Extract at Maximum Concentrations.
Vidal C, Romero L, Lopez-Freire S, Carballada-Gonzalez F, Garcia-Robaina JC, Gonzalez-Fernandez T, Mendez-Brea P, Nieto E, Ruiz-Garcia M. Vidal C, et al. Immun Inflamm Dis. 2024 Dec;12(12):e70090. doi: 10.1002/iid3.70090. Immun Inflamm Dis. 2024. PMID: 39698951 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the safety and tolerability of subcutaneous immunotherapy (SCIT) with mixtures of mite allergen extracts, Dermatophagoides pteronyssinus/Blomia tropicalis (Dpt/Bt) and Dermatophagoides pteronyssinus/Lepidoglyphus destructor (Dpt/Ld …
OBJECTIVE: To assess the safety and tolerability of subcutaneous immunotherapy (SCIT) with mixtures of mite allergen extracts, Dermatopha …
Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial.
Woehlk C, Ramu S, Sverrild A, Nieto-Fontarigo JJ, Vázquez-Mera S, Cerps S, Pulga A, Andreasson LM, Eriksen LL, Dyhre-Petersen N, Menzel M, Klein DK, Hansen S, Uller L, Porsbjerg C. Woehlk C, et al. Am J Respir Crit Care Med. 2023 May 1;207(9):1161-1170. doi: 10.1164/rccm.202209-1708OC. Am J Respir Crit Care Med. 2023. PMID: 36701676 Free PMC article. Clinical Trial.
A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses.
McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. McHugh SM, et al. J Allergy Clin Immunol. 1990 Oct;86(4 Pt 1):521-31. doi: 10.1016/s0091-6749(05)80208-8. J Allergy Clin Immunol. 1990. PMID: 1699985 Clinical Trial.
A double-blind, placebo-controlled trial of immunotherapy was conducted in patients with Dermatophagoides pteronyssinus rhinitis. Thirty patients received an extract with a high content of Der p I (Pharmalgen), 20 received a conventional mite extract (Allpyral), and …
A double-blind, placebo-controlled trial of immunotherapy was conducted in patients with Dermatophagoides pteronyssinus rhinit …
Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial.
Rondón C, Campo P, Salas M, Aranda A, Molina A, González M, Galindo L, Mayorga C, Torres MJ, Blanca M. Rondón C, et al. Allergy. 2016 Jul;71(7):1057-61. doi: 10.1111/all.12889. Epub 2016 Apr 13. Allergy. 2016. PMID: 27008542 Clinical Trial.
We conducted the first randomized, double-blind, placebo-controlled (DBPC), phase II trial of D. pteronyssinus (DP) subcutaneous AIT (DP-AIT) on LAR (clinicaltrials.gov identifier: NCT02123316). ...
We conducted the first randomized, double-blind, placebo-controlled (DBPC), phase II trial of D. pteronyssinus (DP) subcutaneous AIT …
Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial.
Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Zhang J, et al. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. Ann Allergy Asthma Immunol. 2024. PMID: 37913839 Free article. Clinical Trial.
The total nasal symptom score (TNSS), visual analogue scale of nasal symptoms, combined symptom and medication score, mini rhinoconjunctivitis quality of life questionnaire, and serum allergen-specific IgG4 to Dermatophagoides pteronyssinus were all monitored at bas …
The total nasal symptom score (TNSS), visual analogue scale of nasal symptoms, combined symptom and medication score, mini rhinoconjunctivit …
Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy.
Tabar AI, González Delgado P, Sánchez Hernández C, Basagaña Torrento M, Moreno Benítez F, Arina M. Tabar AI, et al. J Investig Allergol Clin Immunol. 2015;25(1):40-6. J Investig Allergol Clin Immunol. 2015. PMID: 25898693 Free article. Clinical Trial.
BACKGROUND: Immunologically enhanced subcutaneous specific immunotherapy (SCIT) has been developed with a fast and simplified updosing phase containing equal parts of the house dust mites (HDM) Dermatophagoides pteronyssinus and Dermatophagoides farinae …
BACKGROUND: Immunologically enhanced subcutaneous specific immunotherapy (SCIT) has been developed with a fast and simplified updosing phase …
452 results